Secarna Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Angel

Secarna Pharmaceuticals General Information

Description

Operator of a profit-making antisense drug discovery and development company intended to meet the medical needs in immuno-oncology and immunology. The company offers third-generation antisense oligonucleotide which encompasses all aspects of drug discovery and pre-clinical development, bringing novel, highly specific, safe, and efficacious app store optimization therapies to patients in the fields of oncology, central nervous system diseases, and beyond, enabling partner companies to discover novel antisense-based therapies for challenging or currently undruggable targets.

Contact Information

Website
www.secarna.com
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Corporate Office
  • Am Klopferspitz 19
  • Martinsried
  • 82152 Planegg
  • Germany
+49 06421
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Vertical(s)
Corporate Office
  • Am Klopferspitz 19
  • Martinsried
  • 82152 Planegg
  • Germany
+49 06421

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Secarna Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Angel (individual) 11-Nov-2019 Completed Startup
To view Secarna Pharmaceuticals’s complete valuation and funding history, request access »

Secarna Pharmaceuticals Patents

Secarna Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023250231-A1 Oligonucleotide for reducing the expression of leucine-rich repeat kinase 2 (lrrk2) and its use for preventing and/or treating human diseases Pending 08-Apr-2022
CA-3241898-A1 Nlrp3 oligonucleotide for use in preventing and/or treating an inflammatory disease Pending 23-Dec-2021
EP-4453213-A1 Nlrp3 oligonucleotide for use in preventing and/or treating an inflammatory disease Pending 23-Dec-2021
AU-2021414304-A1 Oligonucleotides reducing the amount of cd73 mrna and cd73 protein expression Pending 31-Dec-2020
CA-3203395-A1 Oligonucleotides reducing the amount of cd73 mrna and cd73 protein expression Pending 31-Dec-2020 A61K31/7125
To view Secarna Pharmaceuticals’s complete patent history, request access »

Secarna Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Secarna Pharmaceuticals FAQs

  • When was Secarna Pharmaceuticals founded?

    Secarna Pharmaceuticals was founded in 2015.

  • Where is Secarna Pharmaceuticals headquartered?

    Secarna Pharmaceuticals is headquartered in Planegg, Germany.

  • What is the size of Secarna Pharmaceuticals?

    Secarna Pharmaceuticals has 15 total employees.

  • What industry is Secarna Pharmaceuticals in?

    Secarna Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Secarna Pharmaceuticals a private or public company?

    Secarna Pharmaceuticals is a Private company.

  • What is Secarna Pharmaceuticals’s current revenue?

    The current revenue for Secarna Pharmaceuticals is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »